Press coverage about Novartis (NYSE:NVS) has been trending somewhat positive on Saturday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.9537490741932 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Avramopoulos also says he will not appear before Novartis panel (ekathimerini.com)
- Novartis India ex-chief Jawed Zia joins rival Abbott (economictimes.indiatimes.com)
- Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia (globenewswire.com)
- Poised for an FDA pitch, Novartis lays out all its PhIII cards on MS drug siponimod (endpts.com)
- Outlook unclear for Novartis probe (ekathimerini.com)
Several equities analysts recently weighed in on NVS shares. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Nord/LB restated a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. UBS restated a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $87.51.
Shares of NVS stock traded down $1.32 during trading hours on Friday, reaching $78.56. 2,469,903 shares of the company’s stock traded hands, compared to its average volume of 1,669,777. Novartis has a 1 year low of $72.67 and a 1 year high of $94.19. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The company has a market capitalization of $185,118.39, a P/E ratio of 24.17, a PEG ratio of 1.79 and a beta of 0.78.
Novartis (NYSE:NVS) last issued its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The firm had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. During the same quarter in the prior year, the firm earned $1.14 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. equities analysts forecast that Novartis will post 5.33 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2018/03/24/novartis-nvs-earns-daily-media-sentiment-score-of-0-15.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.